Tags

Type your tag names separated by a space and hit enter

Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Brain Res. 1999 Aug 21; 839(1):173-9.BR

Abstract

The purpose of this study was to investigate the cannabinoid and opioid mediated regulation on the effects of central Delta(9)-tetrahydrocannabinol (Delta(9)-THC) administration on hypothalamus-pituitary-adrenal (HPA) axis activity in the male rat. Intracerebroventricular (i.c.v.) administration of delta(9)-THC (25, 50, 100 microg/rat) markedly increased plasma adrenocorticotropin hormone (ACTH) and corticosterone concentrations. Time course effect studies revealed that both hormones secretion peaked at 60 min after Delta(9)-THC i.c.v. administration (50 microg/rat), decreased gradually and returned to baseline levels by 480 min. The i.c.v. administration of the specific cannabinoid receptor antagonist SR-141716A (3 microg/rat) significantly attenuated the increase of both hormones secretion induced by Delta(9)-THC (50 microg/rat). Nevertheless, higher doses (12.5 and 50 microg/rat) of this compound increased both ACTH and corticosterone plasma concentrations. Subcutaneous (s.c.) administration with the opiate receptor antagonist naloxone (0.3 mg/kg) was without effect but significantly diminished the increase of both hormones secretion induced by Delta(9)-THC (50 microg/rat). Taken together, these results indicate that opiate and cannabinoid receptors are involved in the activation of the HPA axis induced by Delta(9)-THC. Furthermore, the increase of ACTH and corticosterone secretion after the administration of higher doses of SR-141716A than those required to block such activation, suggests that endogenous cannabinoids are tonically inhibiting the release of both hormones or that this agonist-like activity may be part of an uncharacterized action of this compound not mediated by cannabinoid receptors.

Authors+Show Affiliations

Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense, 28040, Madrid, Spain. jorgemr@eucmax.sim.ucm.esNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10482810

Citation

Manzanares, J, et al. "Opioid and Cannabinoid Receptor-mediated Regulation of the Increase in Adrenocorticotropin Hormone and Corticosterone Plasma Concentrations Induced By Central Administration of Delta(9)-tetrahydrocannabinol in Rats." Brain Research, vol. 839, no. 1, 1999, pp. 173-9.
Manzanares J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 1999;839(1):173-9.
Manzanares, J., Corchero, J., & Fuentes, J. A. (1999). Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Research, 839(1), 173-9.
Manzanares J, Corchero J, Fuentes JA. Opioid and Cannabinoid Receptor-mediated Regulation of the Increase in Adrenocorticotropin Hormone and Corticosterone Plasma Concentrations Induced By Central Administration of Delta(9)-tetrahydrocannabinol in Rats. Brain Res. 1999 Aug 21;839(1):173-9. PubMed PMID: 10482810.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. AU - Manzanares,J, AU - Corchero,J, AU - Fuentes,J A, PY - 1999/9/14/pubmed PY - 1999/9/14/medline PY - 1999/9/14/entrez SP - 173 EP - 9 JF - Brain research JO - Brain Res VL - 839 IS - 1 N2 - The purpose of this study was to investigate the cannabinoid and opioid mediated regulation on the effects of central Delta(9)-tetrahydrocannabinol (Delta(9)-THC) administration on hypothalamus-pituitary-adrenal (HPA) axis activity in the male rat. Intracerebroventricular (i.c.v.) administration of delta(9)-THC (25, 50, 100 microg/rat) markedly increased plasma adrenocorticotropin hormone (ACTH) and corticosterone concentrations. Time course effect studies revealed that both hormones secretion peaked at 60 min after Delta(9)-THC i.c.v. administration (50 microg/rat), decreased gradually and returned to baseline levels by 480 min. The i.c.v. administration of the specific cannabinoid receptor antagonist SR-141716A (3 microg/rat) significantly attenuated the increase of both hormones secretion induced by Delta(9)-THC (50 microg/rat). Nevertheless, higher doses (12.5 and 50 microg/rat) of this compound increased both ACTH and corticosterone plasma concentrations. Subcutaneous (s.c.) administration with the opiate receptor antagonist naloxone (0.3 mg/kg) was without effect but significantly diminished the increase of both hormones secretion induced by Delta(9)-THC (50 microg/rat). Taken together, these results indicate that opiate and cannabinoid receptors are involved in the activation of the HPA axis induced by Delta(9)-THC. Furthermore, the increase of ACTH and corticosterone secretion after the administration of higher doses of SR-141716A than those required to block such activation, suggests that endogenous cannabinoids are tonically inhibiting the release of both hormones or that this agonist-like activity may be part of an uncharacterized action of this compound not mediated by cannabinoid receptors. SN - 0006-8993 UR - https://www.unboundmedicine.com/medline/citation/10482810/Opioid_and_cannabinoid_receptor_mediated_regulation_of_the_increase_in_adrenocorticotropin_hormone_and_corticosterone_plasma_concentrations_induced_by_central_administration_of_delta_9__tetrahydrocannabinol_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-8993(99)01756-4 DB - PRIME DP - Unbound Medicine ER -